Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Junsheng Wang, MD, PhD
CONTACT
Matt Cromie, MSc
CONTACT
Lead
Jiangsu HengRui Medicine Co., Ltd.
This is a 2-part dose escalation and dose expansion study. Dose escalation uses a modified "3+3" design and continues until a maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified. In part 2, subjects with selected tumor types will be enrolled at the MTD or RP2D.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted